WONDFO BIOTECH(SZ:300482)2022-12-06 11:08Product Overview - The company's main quantitative products include those related to myocardial infarction, heart failure, inflammation assessment, and glycosylated hemoglobin [2] - The growth rate of qualitative products is relatively stable, with no significant increase expected in the near term [2] - New instruments and related quantitative products will be launched in the future, with details available in periodic reports [3] Future Planning - The three-year plan for quantitative products includes expanding the product line, planning for international product platforms, maintaining stable growth in quantitative products, and launching new quantitative products while expanding into overseas markets [3] - The company has research and reserves for raw materials, primarily focusing on biological raw materials [3] - There are currently no plans for external mergers and acquisitions [3] Market Insights - Sales of drug testing products are relatively stable, with future growth expected mainly in regions outside of Europe and the United States [3] - The primary sales channels for reproductive health products are supermarkets, e-commerce, and OTC channels [3] Research and Development - A laboratory was established in San Diego, USA, in 2015, staffed mainly by American-Chinese personnel, focusing on the development of new products and improvement of existing products [4]